Fund is pleased to announce that Open Philanthropy, a grantmaking organization based in San Francisco, California, has awarded funding for efforts to cultivate new partnerships and secure resources ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities ...

Fintel reports that on November 18, 2024, HSBC upgraded their outlook for Moderna (NasdaqGS:MRNA) from Hold to Buy. Analyst ...

The Cystic Fibrosis Foundation is funding the development of a gene editing therapy that is designed to use ReCode’s tissue-specific delivery vehicle to transport gene editing cargo to the lung cells ...

The COVID-19 pandemic has dramatically transformed our understanding of public health, particularly when it comes to ...

The BiaB advantages over traditional methods of RNA manufacturing, include high throughput of high-quality pharmaceutical ...

Advanced genetic testing helped clinicians identify novel SMN1 mutations in two children in China, and correctly diagnose ...

Trace Neuroscience has launched in the U.S. with over $100 million in financing and a goal to develop its UNC13A-targeted ...

Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inha ...

StitchR, a new gene therapy technique, delivers large genes in two parts to treat muscular dystrophies by restoring critical proteins in animal models.

Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is a big problem: size.

Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset——Joint poster with Bachem demonstrates ...